MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

11 Aug 2022 Evaluate
The revenue slipped marginally during the June 2022 quarter. A decline of about Rs. 27869.20 millions was observed as compared to Rs. 28937.50 millions during the corresponding quarter last year.Profit after Tax for the quarter ended June 2022 saw a decline of -43.20% from Rs. 2150.70 millions to Rs. 1221.60  millions.A decline of 2809.70 millions was observed in the OP in the quarter ended June 2022 from 4547.60 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 27869.20 28937.50 -3.69 27869.20 28937.50 -3.69 112871.40 158236.80 -28.67
Other Income 387.10 439.50 -11.92 387.10 439.50 -11.92 6709.90 5898.60 13.75
PBIDT 2809.70 4547.60 -38.22 2809.70 4547.60 -38.22 21443.90 47096.90 -54.47
Interest 78.50 50.60 55.14 78.50 50.60 55.14 169.40 286.80 -40.93
PBDT 2731.20 4497.00 -39.27 2731.20 4497.00 -39.27 20527.40 46810.10 -56.15
Depreciation 1030.50 1146.50 -10.12 1030.50 1146.50 -10.12 4152.60 4880.00 -14.91
PBT 1700.70 3350.50 -49.24 1700.70 3350.50 -49.24 16374.80 41930.10 -60.95
TAX 479.10 1199.80 -60.07 479.10 1199.80 -60.07 1827.70 10801.00 -83.08
Deferred Tax -89.90 -234.60 -61.68 -89.90 -234.60 -61.68 -1969.30 367.60 -635.72
PAT 1221.60 2150.70 -43.20 1221.60 2150.70 -43.20 14547.10 31129.10 -53.27
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 10.08 15.72 -35.85 10.08 15.72 -35.85 19.00 29.76 -36.17
Peers
Company Name CMP
Sun Pharma. Inds. 1752.50
Dr. Reddys Labs. 1180.00
Cipla 1305.00
Lupin 1942.00
Zydus Lifesciences 1115.20
View more..